Obesity Drugs Panel To Mull Whether Products Without CV Signal Need Outcomes Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The Endocrinologic and Metabolic Drugs Advisory Committee also will evaluate methods for collecting cardiovascular risk information for obesity drugs with a CV safety signal, as FDA seeks input on when and how sponsors should evaluate their products.
You may also be interested in...
FDA Clears Belviq With Post Hoc Finding Of Less Than Double Placebo CV Risk
In analyses of both a narrow and a broad search for cardiovascular events in lorcaserin’s clinical trials, the upper bound of the 95% confidence level was less than 2.0, allowing marketing with a full CV outcomes trial to come post-approval, FDA briefing documents reveal.
CV Trials For Obesity Drugs Won’t Be Conducive To Easy Interpretation, Panel Indicates
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will discuss design issues March 29 and vote on the need for pre-approval trials in drugs without a CV safety signal.
Orexigen Agreement On Contrave CV Trial Hints At FDA’s Thinking On Obesity
FDA appears to be testing weight loss agents against an easier-to-meet threshold for cardiovascular risk compared to diabetes drugs, based on Orexigen Therapeutics Inc.’s announcement of an agreement with the agency on a cardiovascular outcomes trial for its obesity agent Contrave (naltrexone/bupropion).